DMD Bio-Rad Microplate Reader

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on May 12, 2008; DOI: 10.1124/dmd.108.020867

0090-9556/08/3608-1716-1721$20.00
DMD 36:1716-1721, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.020867v1
36/8/1716    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Merrell, M. D.
Right arrow Articles by Cherrington, N. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Merrell, M. D.
Right arrow Articles by Cherrington, N. J.

The Nrf2 Activator Oltipraz Also Activates the Constitutive Androstane Receptor

Matthew D. Merrell, Jonathan P. Jackson, Lisa M. Augustine, Craig D. Fisher, Angela L. Slitt, Jonathan M. Maher, Wendong Huang, David D. Moore, Youcai Zhang, Curtis D. Klaassen, and Nathan J. Cherrington

Department of Pharmacology and Toxicology, University of Arizona, Tucson, Arizona (M.D.M., J.P.J., L.M.A., C.D.F., N.J.C.); Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (A.L.S.); Tsukuba Advanced Research Alliance Center, University of Tsukuba Tennoudai, Tsukuba-shi, Ibaraki, Japan (J.M.M.); Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (W.H., D.D.M.); and Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas (Y.Z., C.D.K.)

Oltipraz (OPZ) is a well known inducer of NAD(P)H:quinone oxidoreductase (NQO1) along with other enzymes that comprise the nuclear factor E2–related factor 2 (Nrf2) battery of detoxification genes. However, OPZ treatment also induces expression of CYP2B, a gene regulated by the constitutive androstane receptor (CAR). Therefore, this study was designed to determine whether OPZ induces gene expression in the mouse liver through activation of CAR in addition to Nrf2. OPZ increased the mRNA expression of both Cyp2b10 and Nqo1 in C57BL/6 mouse livers. As expected, in livers from Nrf2-/- mice, OPZ induction of Nqo1 was reduced, indicating Nqo1 induction is dependent on Nrf2 activation, whereas Cyp2b10 induction was unchanged. The robust induction of Cyp2b10 by OPZ in wild-type mice was completely absent in CAR-/- mice, revealing a CAR-dependent induction by OPZ. OPZ also induced transcription of the human CYP2B6 promoter-reporter containing the phenobarbital (PB) responsive element in mouse liver using an in vivo transcription assay. Additionally, OPZ induced in vivo nuclear accumulation of CAR at 3 h but, as with PB, was unable to reverse androstanol repression of mouse CAR constitutive activity in transiently transfected HepG2 cells. In summary, OPZ induces expression of Cyp2b10 and Nqo1 via the activation of CAR and Nrf2, respectively.

Address correspondence to: Nathan J. Cherrington, University of Arizona, 1703 East Mabel Street, Tucson, AZ 85721. E-mail: cherrington{at}pharmacy.arizona.edu






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.